NASDAQ · ALVO
Healthcare · Drug Manufacturers - Specialty & Generic
$5.21
Up+$0.03 (+0.58%)
Updated Sep 10, 2026, 10:19 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ALVO closed at $5.21 after 20 trading sessions, up 29.93% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $5.15 | $5.24 | $5.06 | $5.21 | 572.36K |
| Sep 8, 2026 | $5.26 | $5.32 | $5.142 | $5.19 | 632.64K |
| Sep 4, 2026 | $5.31 | $5.40 | $5.205 | $5.32 | 535.4K |
| Sep 3, 2026 | $5.37 | $5.47 | $5.275 | $5.38 | 673.7K |
| Sep 2, 2026 | $5.24 | $5.415 | $5.171 | $5.34 | 700.3K |
| Sep 1, 2026 | $5.08 | $5.265 | $4.98 | $5.24 | 1.03M |
| Aug 31, 2026 | $5.00 | $5.265 | $4.98 | $5.19 | 1.25M |
| Aug 28, 2026 | $4.84 | $5.00 | $4.82 | $4.95 | 878.46K |
| Aug 27, 2026 | $4.88 | $4.9792 | $4.785 | $4.88 | 967.69K |
| Aug 26, 2026 | $4.98 | $4.99 | $4.782 | $4.91 | 890.18K |
| Aug 25, 2026 | $5.24 | $5.39 | $5.015 | $5.05 | 1.77M |
| Aug 24, 2026 | $4.79 | $5.359 | $4.715 | $5.25 | 3.18M |
| Aug 21, 2026 | $4.32 | $4.595 | $4.32 | $4.43 | 2.27M |
| Aug 20, 2026 | $3.89 | $4.37 | $3.75 | $4.27 | 1.37M |
| Aug 19, 2026 | $4.00 | $4.08 | $3.94 | $3.99 | 546.9K |
| Aug 18, 2026 | $3.92 | $4.00 | $3.83 | $3.95 | 675.58K |
| Aug 17, 2026 | $4.04 | $4.04 | $3.77 | $3.88 | 591.72K |
| Aug 14, 2026 | $4.15 | $4.185 | $3.985 | $4.055 | 607.27K |
| Aug 13, 2026 | $3.98 | $4.14 | $3.84 | $4.09 | 559.86K |
| Aug 12, 2026 | $3.81 | $4.02 | $3.76 | $4.01 | 921.39K |
The latest Smart Investors Daily articles mentioning ALVO.
ALVO research
Company profile and research snapshot.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | B of A Securities | Buy | — |
| Aug 14, 2026 | Evercore ISI Group | Outperform | — |
| Mar 24, 2026 | UBS | Buy | — |
| Mar 24, 2026 | Barclays | Underweight | — |
| Dec 9, 2025 | Barclays | Underweight | — |
No generated briefing is available yet.
Yahoo · Aug 24, 2026
Alvotech (NASDAQ:ALVO) extended its winning streak to a 5th consecutive day on Monday, jumping 18.51 percent to finish at $5.25 apiece, after the Bank of America (BofA) raised its price target for the company. In its recent coverage, BofA initiated a buy recommendation on Alvotech shares with a price target of $7, amid the closure […]
Yahoo · Aug 24, 2026
Investing.com -- BofA Securities initiated coverage of Alvotech S.A. with a “buy” rating and a $7 price objective, versus the stock’s $4.43 price as of Monday, after the FDA’s closure of its inspection of the company’s Reykjavik manufacturing facility removed a key regulatory overhang and as the biosimilar developer enters what BofA called its most meaningful launch cycle since inception.
Benzinga · Aug 24, 2026
B of A Securities analyst Jason Gerberry initiates coverage on Alvotech (NASDAQ:ALVO) with a Buy rating and announces Price Target of $7.
Yahoo · Aug 21, 2026
REYKJAVIK, ICELAND (August 21, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical (TWSE Stock Code: 1795) covering two of Alvotech’s candidates in the United States and selected Asian markets: AVT34, a proposed biosimilar to Imfinzi® (durvalumab), and AVT87, a proposed biosimilar to H
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ALVO.
